HUTCHMED (China) ( (HK:0013) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
HUTCHMED (China) stocks are on the rise following the announcement of upcoming presentations at the ESMO Congress 2025, where they will showcase new clinical data on their oncology treatments, including drugs like fruquintinib and savolitinib. This move underscores the company’s dedication to enhancing its role in the cancer treatment sector. Despite these promising developments, analysts maintain a Hold rating on the stock, indicating cautious optimism.
More about HUTCHMED (China)
YTD Price Performance: -1.70%
Average Trading Volume: 43,641
Technical Sentiment Signal: Sell
Current Market Cap: £2.09B
For further insights into 0013 stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.